A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

被引：0
|
作者：
Chi, K. N.
Beardsley, E. K.
Venner, P. M.
Eigl, B. J.
Hotte, S. J.
Ko, Y.
Saad, F.
Winquist, E.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Juravinski Canc Ctr, Hamilton, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] London Hlth Sci Ctr, London, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5166
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized dose-finding phase II study of ifosfamide (IF) in metastatic hormone-refractory prostate cancer (HRPC).
    Hervonen, P
    Lehtinen, T
    Tammela, TLJ
    Kellokumpu-Lehtinen, P
    ANNALS OF ONCOLOGY, 2000, 11 : 76 - 76
  • [22] A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC)
    Hervonen, P
    Lehtinen, T
    Tammela, TL
    Kellokumpu-Lehtinen, P
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2002, 21 (02) : 177 - 180
  • [23] Satraplatin (S) increases progression-free survival (PFS) and delays pain progression in patients (PTS) with hormone refractory prostate cancer (HRPC) that have progressed after prior docetaxel
    Stemberg, N.
    Sartor, O. A.
    Petrylak, O. P.
    Witjes, F.
    Bodrogi, I
    Harper, P.
    James, N.
    Demkov, T.
    Eymard, J-C
    Wirth, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 230 - 230
  • [24] Phase I study of picoplatin and docetaxel (D) with prednisone (P) in patients (pts) with chemotherapy-naive metastatic hormone refractory prostate cancer (HRPC)
    Roman, L.
    Karlov, P.
    Kaprin, A.
    Gladkov, O.
    Breitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
    Eymard, J.-C.
    Priou, F.
    Zannetti, A.
    Ravaud, A.
    Lepille, D.
    Kerbrat, P.
    Gomez, P.
    Paule, B.
    Genet, D.
    Herait, P.
    Ecstein-Fraisse, E.
    Joly, F.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 1064 - 1070
  • [26] Prognostic role of chromogranin a expression for docetaxel response in metastatic hormone-refractory prostate cancer (HRPC)
    Gernone, Angela
    Trabucco, Senia
    Pagliarulo, Vincenzo
    Troccoli, Giuseppe
    Pagliarulo, Arcangelo
    ANNALS OF ONCOLOGY, 2007, 18 : 65 - 65
  • [27] Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
    Machiels, J. H.
    Mazzeo, F.
    Clausse, M.
    Filleul, B.
    Marcelis, L.
    Honhon, B.
    D'Hondt, L.
    Dopchie, C.
    Bonny, M.
    Kerger, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study
    Font, A
    Murias, A
    Arroyo, FRG
    Martin, C
    Areal, J
    Sanchez, JJ
    Santiago, JA
    Constenla, M
    Saladie, JM
    Rosell, R
    ANNALS OF ONCOLOGY, 2005, 16 (03) : 419 - 424
  • [29] First-line chemotherapy with docetaxel in hormone-refractory metastatic prostate cancer patients: A monoinstitutional phase II study
    Bernardo, A.
    Palumbo, R.
    Strada, M. R.
    Poggi, G.
    Teragni, C.
    Delmonte, A.
    Canto, A. M.
    Frascaroli, M.
    Jedrychowska, I
    Bernardo, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI81 - XI82
  • [30] Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)
    Nilsson, S.
    Franzen, L.
    Tyrrel, C.
    Blom, R.
    Tennvall, J.
    Lennernas, B.
    Johannessen, D. C.
    Sokal, M.
    Parker, C.
    Bruland, O. S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 295 - 295
12345